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Abstract
 
Heat shock protein 70 (Hsp70) is a potent survival protein whose depletion triggers massive
caspase-independent tumor cell death. Here, we show that Hsp70 exerts its prosurvival function
by inhibiting lysosomal membrane permeabilization. The cell death induced by Hsp70 depletion
was preceded by the release of lysosomal enzymes into the cytosol and inhibited by pharmaco-
logical inhibitors of lysosomal cysteine proteases. Accordingly, the Hsp70-mediated protection
against various death stimuli in Hsp70-expressing human tumor cells as well as in immortalized
Hsp70 transgenic murine fibroblasts occurred at the level of the lysosomal permeabilization.
On the contrary, Hsp70 failed to inhibit the cytochrome 
 
c
 
–induced, apoptosome-dependent
caspase activation in vitro and Fas ligand–induced, caspase-dependent apoptosis in immortalized
fibroblasts. Immunoelectron microscopy revealed that endosomal and lysosomal membranes of
tumor cells contained Hsp70. Permeabilization of purified endo/lysosomes by digitonin failed
to release Hsp70, suggesting that it is physically associated with the membranes. Finally, Hsp70
positive lysosomes displayed increased size and resistance against chemical and physical mem-
brane destabilization. These data identify Hsp70 as the first survival protein that functions by
inhibiting the death-associated permeabilization of lysosomes.
Key words: cathepsins • cell death • neoplasms • tumor necrosis factor • 
immunoelectron microscopy
 
Introduction
 
Defects in signaling pathways leading to the classic mito-
chondrion- and caspase-mediated apoptosis are frequent in
primary tumors (1, 2). As a result, alternative cell death
programs are gaining increasing interest among cancer re-
searchers. Until recently, lysosomes have been considered
“suicide bags” that, through the release of unspecific enzymes,
cause autolysis and damage neighboring cells during uncon-
trolled tissue damage. However, accumulating data now show
that lysosomes also function as death signal integrators in
many controlled death paradigms (3, 4). Lysosomal pro-
teases and cathepsins translocate from the lysosomal lumen
to the cytosol in response to a wide variety of death stimuli
such as TNF (5, 6), Fas (7), p53 activation (8), microtubule
stabilizing agents (9), oxidative stress (7, 10), staurosporine
(11), growth factor deprivation (7), and lysosomotropic
agents (10, 12). Once released to the cytosol, cathepsins,
especially cysteine cathepsins B and L and aspartyl cathepsin
D, may trigger the mitochondrial outer membrane perme-
abilization followed by caspase- or apoptosis-inducing factor–
mediated apoptosis (5, 8, 11–13) or mediate caspase- and/
or apoptosis-inducing factor–independent programmed cell
death (PCD) with apoptosis- or necrosis-like morphology (6,
14). Because the latter pathway can circumvent most of the
known resistance mechanisms occurring in tumor cells, ly-
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sosomal membrane permeabilization (LMP) appears to be a
promising target for novel cancer drugs.
The heat shock protein 70 (Hsp70) family of proteins
consists of both constitutively expressed and stress-induc-
ible molecular chaperones that are localized to different in-
tracellular compartments (15). The major stress-inducible
Hsp70 (also called Hsp72) is highly expressed in the cytosol
and plasma membrane of primary tumors of various origins,
whereas its expression in unstressed normal cells is very low
and restricted to the cytosol (15–17). The role of Hsp70 in
tumorigenesis is supported by experimental data showing
that its high expression is required for the growth of human
tumor xenografts in immunodeficient mice (18), and that it
enhances the tumorigenic potential of rodent cells in syn-
genic animals (19). Furthermore, its high expression corre-
lates with poor therapeutic outcome in human breast cancer
(20). The molecular mechanism underlying the tumori-
genic potential of Hsp70 is as yet unclear, but it may be ex-
plained by its ability to confer resistance to both apoptosis-
and necrosis-like PCD induced by diverse stimuli (21, 22).
In vitro studies have suggested that Hsp70 may directly in-
terfere with the apoptosis signaling machinery by binding
to the apoptotic protease-activating factor-1 (22) or apop-
tosis-inducing factor (23) and thereby inhibit the apopto-
some-mediated activation of caspases or apoptosis-inducing
factor–induced nuclear changes, respectively. However, most
studies using cellular death models suggest that Hsp70-
mediated inhibition of caspase-mediated PCD occurs up-
stream of mitochondrial outer membrane permeabilization
and apoptosome formation (24–26). Furthermore, Hsp70
can effectively rescue cells from caspase-independent PCD
induced by TNF, heat shock, serum starvation, or oxida-
tive stress (6, 23, 24, 27, 28), and the depletion of Hsp70
induces caspase-independent apoptosis-like PCD in various
human tumor cell lines (18, 29). Here, we aim at determin-
ing the mechanism through which Hsp70 regulates tumor
cell survival with special focus on LMP and caspase-inde-
pendent cell death.
 
Materials and Methods
 
Cell Culture. 
 
WEHI-V2 and WEHI-V3 are vector-trans-
fected and WEHI-hsp-2 and WEHI-hsp-18 Hsp70-transfected
single cell clones of WEHI-S murine fibrosarcoma cells (28).
ME-180v and ME-180as are single cell clones of ME-180 human
cervix carcinoma cells transfected with vector and Hsp70 anti-
sense (as) cDNA, respectively (28). HeLa human cervix carci-
noma cell line was provided by J. Lukas (Danish Cancer Society,
Copenhagen, Denmark). CX
 
 
 
 (
 
 
 
90% of cell positive) and CX
 
 
 
(
 
 
 
20% of cells positive) cells are stable sublines of CX2 human
colon carcinoma cells sorted according to the Hsp70 surface ex-
pression (17). HBL-100 is an immortalized breast epithelial cell
line provided by P. Briand (Danish Cancer Society, Copenhagen,
Denmark). Murine embryonic fibroblasts (MEFs) explanted from
days 14–16 wild type or homozygote Hsp70 transgenic CBA 
 
 
 
C57Bl/6 mice (provided by G. Kollias, Hellenic Pasteur Insti-
tute, Athens, Greece, and G. Pagoulatos, University of Ioannina,
Ioannina, Greece; reference 30) embryos were passaged once a
week (6–8,000 cells/cm
 
2
 
) with a change of medium on day three
until they reached senescence. Senescent cells were maintained
by medium change twice a week, and passaging was restarted
upon immortalization. Immortalized MEFs (iMEFs) were used at
passages 15–20. DMEM (Invitrogen) supplemented with 10%
heat-inactivated calf serum (Biological Industries), 0.1 mM of
nonessential amino-acids (Invitrogen), 110 mg/ml Na-pyruvate
(Merck) and antibiotics were used as growth medium for MEFs.
Other cells were propagated in RPMI 1640 (Invitrogen) supple-
mented with 6% heat-inactivated calf serum and antibiotics
(complete medium) at 37
 
 
 
C in a humidified air atmosphere with
5% CO
 
2
 
. All cells were repeatedly tested and found negative for
mycoplasma by Hoechst (H-33342; Molecular Probes) staining
and immunofluorescence microscopy.
 
Cell Death Induction and Determination. 
 
Ad.asHsp70 and Ad.
 
 
 
-Gal
are adenoviral (Ad.) shuttle vectors carrying bases 475–796 of the
published human Hsp70 sequence in as orientation and 
 
 
 
-galac-
tosidase (
 
 
 
-Gal) cDNA, respectively (29). The infections were
performed as described previously using the lowest multiplicity of
infection resulting in a 100% infection (29). Recombinant human
TNF was provided by A. Cerami (Kenneth S. Warren Laborato-
ries, Tarrytown, NY), recombinant murine TNF was obtained
from R&D Systems, and etoposide and hydrogen peroxide were
obtained from Sigma-Aldrich. To obtain Fas ligand–containing
supernatant, confluent Neuro2 cells were provided with fresh se-
rum-free medium, and after 24 h at 37
 
 
 
C, the supernatant was
collected, centrifuged at 600 
 
g
 
 for 10 min, and stored in aliquots
at 
 
 
 
80
 
 
 
C. The blue light was delivered to CX cells by a custom-
made lamp house consisting of a 100-W Hg gas discharge lamp, a
bp filter (450–500 nm), and a mirror system (Leica) and to iMEFs
by the 488-nm laser of the Axiovert 100M confocal microscope
(Carl Zeiss MicroImaging, Inc.). 
 
 
 
-irradiation was delivered to
exponentially growing cells by a 
 
137
 
Cs source at a dose rate of 1
Gy/10 s.
z-Val-Ala-DL-Asp-CH
 
2
 
F (zVAD-fmk) obtained from Bachem,
PD150606 obtained from Calbiochem-Novabiochem, CA-074-
Me obtained from Peptides International, z-Phe-Ala-CH
 
2
 
F (zFA-
fmk) obtained from Enzyme System Products, Mu-Leu-HphVSPh
(LHVS; provided by J. Palmer, Celera, San Francisco, CA; refer-
ence 31), and Ac-Asp-Glu-Val-Asp-aldehyde (DEVD-CHO)
obtained from BIOMOL Research Laboratories, Inc. were dis-
solved in DMSO. When using the protease inhibitors, DMSO
concentration of all samples was adjusted to 0.2%. The experi-
ments with ME-180 transfectants were performed in RPMI 1640
supplemented with 0.5% FCS after a preincubation of cells in this
medium for 18–24 h. Experiments with other cells were per-
formed in complete medium.
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction and lactate dehydrogenase (LDH) release assays
(cytotoxicity detection kit; Roche) were used to analyze the
survival of the cells as described previously (6). Staining with an-
nexin V conjugated with fluorescein isothiocyanate (Bender Med-
systems) and flow cytometry (FACSCalibur™; Becton Dickinson)
analysis were used to detect apoptotic cells exposing phosphati-
dylserine on the outer leaflet of the plasma membrane.
 
Measurement of Enzyme Activities. 
 
To measure cytosolic en-
zyme activities, subconfluent cells were treated with an extraction
buffer (250 mM sucrose, 20 mM Hepes, 10 mM KCl, 1.5 mM
MgCl
 
2
 
, 1 mM EDTA, 1 mM EGTA, and 1 mM pefabloc, pH
7.5) containing 15 
 
 
 
g/ml digitonin for 12–15 min on ice. The
digitonin concentration and treatment times were optimized to
result in the total release of the cytosolic LDH activity without
disruption of lysosomes. To measure the total cellular cysteine ca-
thepsin activity, cells were treated with the aforementioned ex- 
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traction buffer containing 200 
 
 
 
g/ml digitonin for 12–15 min on
ice and, when indicated, incubated with the indicated protease
inhibitors or recombinant human Hsp70 (rhHsp70; StressGen
Biotechnologies) for 30 min on ice before the measurement. The
effector caspase and cysteine cathepsin activities were estimated
by adding one volume of 20 
 
 
 
M Ac-DEVD–7-amino-trifluo-
romethylcoumarin (AFC) (BIOMOL Research Laboratories,
Inc.) in caspase reaction buffer (100 mM Hepes, 20% glycerol,
0.5 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol (DTT), and
1 mM pefabloc, pH 7.5) or 20 
 
 
 
M zFR-AFC (Enzyme System
Products) in cathepsin reaction buffer (50 mM sodium acetate, 4
mM EDTA, 8 mM DTT, and 1 mM pefabloc, pH 6.0), respec-
tively. The V
 
max
 
 of the liberation of AFC (excitation, 400 nm;
emission, 489 nm) was measured for 20 min at 30
 
 
 
C with a Spec-
tramax Gemini fluorometer (Molecular Devices). 
 
 
 
-
 
N
 
-acetyl-
glucosaminidase (NAG) activity was estimated by adding three
volumes of 0.2 M sodium citrate buffer, pH 4.5, containing 300
 
 
 
g/ml 4-methylumbelliferyl-2-acetamido-2-deoxy-
 
 
 
-
 
d
 
-glucopy-
ranoside (Sigma-Aldrich). The V
 
max
 
 of the liberation of methyl-
umbelliferyl (excitation, 356 nm; emission, 444 nm) was measured
for 20 min at 30
 
 
 
C with a Spectramax Gemini fluorometer. LDH
activity of the cytosol determined by a cytotoxicity detection kit
(Roche) was used as an internal standard with which protease ac-
tivities were normalized.
 
In Vitro Apoptosome Assay. 
 
Subconfluent cultures of HeLa
cells were harvested by scraping on ice, washed in ice-cold PBS,
and resuspended in equal volume of ice-cold isotonic lysis buffer
(20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl
 
2
 
, 1
mM EDTA, 1 mM EGTA, 250 mM sucrose, 1 mM DTT, 10
 
 
 
g/ml aprotinin, 1 
 
 
 
g/ml leupeptin, 1 
 
 
 
g/ml pepstatin A, and
100 
 
 
 
g/ml pefabloc). After a 30-min incubation on ice, the cells
were lysed by 30 strokes of a Dounce homogenizer and centri-
fuged at 750 
 
g
 
 for 10 min. The obtained supernatant was further
centrifuged at 10,000 
 
g
 
 for 10 min and at 20,000 
 
g
 
 for 30 min.
The clarified supernatant was removed carefully, stored in ali-
quots at 
 
 
 
80
 
 
 
C, and used at protein concentrations ranging from
5 to 10 mg/ml. The apoptosome was activated by the addition of
1 mM dATP (dissolved in ddH
 
2
 
0 and adjusted to pH 7.0; ICN
Biomedicals) and 1 
 
 
 
M horse heart cytochrome 
 
c
 
 (Sigma-Aldrich)
to the cytosolic HeLa cell extract (protein concentration; 5–10
mg/ml) containing 100 
 
 
 
M DEVD-AFC (BIOMOL Research
Laboratories, Inc.). When indicated, 2 
 
 
 
M recombinant human
Hsp70 (StressGen Biotechnologies) was added to the cytosolic
extract before the addition of cytochrome 
 
c
 
 and dATP. After a
30-min incubation at 37
 
 
 
C, the V
 
max
 
 of the liberation of AFC
was measured as mentioned before. After 2 h at 37
 
 
 
C, the sam-
ples from the in vitro apoptosome assay were mixed with 0.25
volumes of 4 
 
 
 
 Laemmli sample buffer and the immunodetec-
tion of proteins separated by SDS-PAGE was performed as de-
scribed in the next paragraph.
 
Immunoblot Analysis, Immunocytochemistry, and Electron Micros-
copy. 
 
The primary antibodies used included murine monoclonal
antibodies against human Hsp70 (Multimmune GmbH), cathep-
sin B (Oncogene Research Products), cathepsin L and DFF45/
ICAD (Transduction Laboratories), caspase-3 and -9 (BD Bio-
sciences), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Biogenesis), as well as polyclonal goat antibodies against rat
cathepsin B (32), rabbit antibodies against human cathepsin D
(no. 06-467; Upstate Biotechnology), and rabbit antiserum against
Hsp70 raised (Neosystem) by immunizing a rabbit with an oval-
bumin-coupled peptide (YTKDNNLLGRFELSG) correspond-
ing to amino acids 450–463 in the human Hsp70 sequence
(P08107). Immunodetection of proteins (20 
 
 
 
g/lane) separated
by 8–10% SDS-PAGE and transferred to nitrocellulose was per-
formed using ECL Western blotting reagents (Amersham Bio-
sciences), and the indicated primary antibodies and appropriate
secondary antibodies were obtained from DakoCytomation.
To visualize cathepsins and cytochrome 
 
c
 
, cells were fixed in
 
 
 
20
 
 
 
 methanol for 10 min at 25
 
 
 
C and 4% formaldehyde for 30
min followed by 0.1% Triton for 10 min at 25
 
 
 
C, respectively.
After blocking for 30 min in 10% FCS, slides were stained with
the indicated primary antibodies and biotinylated (cathepsin B;
DakoCytomation) or Alexa Fluor488–conjugated anti–mouse
IgG (Molecular Probes). The indicated nuclei were stained in the
end with 2 
 
 
 
l/ml ethidium bromide for 1–2 min at 25
 
 
 
C pre-
ceded by the 10-min treatment with 0.5 mg/ml RNase A at
37
 
 
 
C. Biotinylated IgG was visualized by peroxidase-conjugated
streptavidin–biotin complex and diaminobenzidine/H
 
2
 
O
 
2
 
 accord-
ing to the manufacturer’s instructions (SteptABC; Vector Labora-
tories) and images were taken with a digital camera mounted on a
BX60 microscope (Olympus). Confocal images were obtained
with an Axiovert 100M microscope equipped with LSM 510 sys-
tem (Carl Zeiss MicroImaging, Inc.).
For immunoelectron microscopy, CX
 
 
 
 and CX
 
 
 
 tumor cells
were fixed in 8% paraformaldehyde in 250 mM Hepes buffer for
1 h. After two washes, free aldehyde groups were quenched with
50 mM NH
 
4
 
Cl for 10 min. For cryoprotection, the cell pellets
were incubated in 2.1 M sucrose in 17% polyvinylpyrrolodone at
20
 
 
 
C for 30 min before freezing in liquid nitrogen. Ultrathin sec-
tions (70 nm) were cut at 
 
 
 
100
 
 
 
C on an Ultracut E microtome
(FC4E; Reichart-Jung) using a glass knife and mounted on 150-
mesh Parlodion (Mallinckrodt Specialty Chemicals)–coated nickel
grids. Immunogold labeling of Hsp70 was performed with 10-nm
gold particles and of cathepsin D with 5-nM gold particles. In
brief, the grids were rinsed and blocked in 0.1% acetylated BSA
buffer before incubation with murine anti-Hsp70 antibody (1:100)
and/or rabbit anti-cathepsin D antibody (1:200) for 18 h at 4
 
 
 
C.
After washing, the grids were incubated individually (single stain-
ing) or subsequently (double staining) for 3 h at 25
 
 
 
C in 1% BSA
buffer containing 1:75 dilutions of Aurion goat anti–mouse IgG/
IgM (10 nm GP) and goat anti–rabbit IgG (5 nm GP; both from
Amersham Biosciences). Nonspecific binding was blocked by ex-
tensive washing in 0.1% acetylated BSA buffer. An additional fix-
ation in 2% glutaraldehyde in PBS was performed after immuno-
staining. The sections were stained in uranyl acetate/methyl
cellulose and viewed in an EM 10CR electron microscope (Carl
Zeiss MicroImaging, Inc.). This method is optimized to the lo-
calization of antigens that are localized in both intracellular and
extracellular compartments.
 
Fractionation of iMEFs. 
 
Subconfluent cultures of iMEF-Hsp-4
cells were harvested by scraping on ice, washed in ice-cold PBS,
and resuspended (20 
 
 
 
 10
 
6
 
 cells/ml) in ice-cold SCA buffer (20
mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 250 mM sucrose, 1 mM DTT, 10 
 
 
 
g/ml
aprotinin, 1 
 
 
 
g/ml leupeptin, 1 
 
 
 
g/ml pepstatin A, and 1 mM
pefabloc). After a 30-min incubation on ice, cells were lysed by
30–40 strokes in a Dounce homogenizer and centrifuged at 750 
 
g
 
for 5 min. The pellet was collected as the heavy membrane frac-
tion (intact cells and nuclei). The supernatant obtained was cen-
trifuged at 750 
 
g
 
 for 5 min, the pellet was discarded, and the new
supernatant was divided into two tubes and further centrifuged at
20,000 
 
g
 
 for 20 min. The resulting supernatants were collected as
the cytosolic fraction. The pellets were resuspended in 450 
 
 
 
l
SCA buffer with or without 800 
 
 
 
g/ml digitonin, incubated for
30 min on ice, and centrifuged at 20,000 
 
g
 
 for 20 min. The pel-
lets were collected as the light membrane fractions (cellular or- 
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ganelles including endosomes and lysosomes) and the superna-
tants as the supernatants of the light membrane fraction (without
digitonin; washing buffer and with digitonin; the contents of per-
meabilized cellular organelles). All fractions were mixed with 1:3
volumes of 3
 
  
 
Laemmli sample buffer and subjected to immuno-
blot analysis.
 
Lysosomal Volume and Permeability Assessment. 
 
To label lyso-
somes, cells were incubated with 5 
 
 
 
M acridine orange (Molecu-
lar Probes) for 15 min at 37
 
 
 
C and washed twice with PBS before
the indicated treatments or measurements. Acridine orange is a
metachromatic fluorochrome and a weak base that exhibits red
fluorescence when highly concentrated in acidic lysosomes and
green fluorescence when outside the lysosomes. Total lysosomal
volume and lysosomal integrity were evaluated by assessing the
red fluorescence (FL2) and green fluorescence (FL1), respec-
tively, by flow cytometry using a flow cytometer (Becton Dick-
inson) or confocal microscopy (Axiovert 100M microscope
equipped with LSM 510 system; Carl Zeiss MicroImaging, Inc.).
 
Results
 
Hsp70 Depletion Triggers LMP Followed by Cathepsin-medi-
ated PCD.
 
We have shown recently that the depletion of
Hsp70 by adenoviral transfer of antisense Hsp70 cDNA
(Ad.asHsp70) induces massive caspase-independent PCD in
diverse tumor cell lines, but not in nontumorigenic epithe-
lial cells or fibroblasts (18, 29). To find clues to the tumor-
specific death pathway suppressed by Hsp70, we analyzed
the ability of various protease inhibitors to rescue tumor
cells from the death induced by Hsp70 depletion. Remark-
Figure 1. Ad.asHsp70 induces LMP and cathepsin-mediated PCD. (A and B) MCF-7 (A) and MDA-MB-468 (B) breast cancer cells were left un-
treated or infected with Ad. -Gal or Ad.asHsp70. 6 h later, cells were trypsinized and plated on a 96-well plate at a density of 6,000 cells/well. After an
additional 6 h (MCF-7) or 18 h (MDA-MB-468), the indicated protease inhibitors at indicated concentrations were added, and 72 h after the infection,
the survival of the cells was determined by the MTT assay. The survival of Ad. -Gal–treated cells is expressed as a percentage of noninfected cells and
that of Ad.asHsp70-infected cells as a percentage of Ad. -Gal–infected cells treated with the same inhibitors. (C) The cysteine cathepsin activity in
WEHI-S cell lysates (4   105 cells/ml) containing indicated concentrations of recombinant Hsp70 were measured using zFR-AFC as a fluorogenic
probe. The specificity of the assay for cysteine cathepsins was demonstrated by the ability of 1  M zFA-fmk, but not 1  M zVAD-fmk, to attenuate the
protease activity. (D–F) MCF-7 cells were stained with antibodies against human cathepsin B (D and E) or L (F) 65 h after the infection with Ad. -Gal
(D) or Ad.asHsp70 (E and F) and visualized using biotinylated (D and E) or FITC-coupled (F) secondary antibodies. Representative fields are shown, and
cells with cathepsins released into the cytosol are marked with arrows. (G–I) MCF-7 (G and H) and HBL-100 (I) cells were infected with Ad. -Gal or
Ad.asHsp70, and the cysteine cathepsin (G and I) and NAG (H) activities of digitonin-extracted cytosols and total cellular lysates were analyzed at the
indicated time points. The results are expressed as percentages of the cytosolic activity of the total activity and corrected for the LDH activity. The values
represent means of triplicate determinations. *, P   0.02l; **, P   0.01. All experiments were repeated two to four times with essentially similar results.Nylandsted et al. 429
ably, the inhibition of cysteine cathepsin activity by broad
spectrum cysteine cathepsin inhibitors zFA-fmk (6) and
LHVS (31) or high concentrations of zVAD-fmk (6) con-
ferred significant protection against Ad.asHsp70-induced
death in MCF-7 and MDA-MB-468 breast cancer cells
(Fig. 1, A and B). A more specific inhibition of cathepsin B
by CA-074-Me conferred smaller, but significant, protec-
tion in MCF-7 cells. Due to an unspecific toxicity CA-
074-Me and LHVS in the long-term assay, they could not
be applied to MDA-MB-486 and MCF-7 cells, respec-
tively. As we have shown earlier, selective inhibition of
caspases by DEVD-CHO at concentrations up to 200  M
(not depicted) or low concentrations of zVAD-fmk ( 50
 M) did not increase the survival of Ad.asHsp70-treated
MCF-7 cells (Fig. 1 A), whereas such treatments conferred
complete protection against TNF-induced apoptosis in
MCF-7 cells (33). Also, 50  M PD150606 capable of in-
hibiting calpain activation in MCF-7 cells was unable to
rescue cells from Ad.asHsp70 (unpublished data).
Hsp70 could protect tumor cells from cysteine cathep-
sin-mediated PCD either via the direct inhibition of the
cysteine cathepsin activity or the inhibition of the LMP.
To test the first possibility, we measured the cysteine ca-
thepsin activity in tumor cell lysates incubated with or
without recombinant Hsp70. Although 1  M zFA-fmk
and high concentrations (100  M) of zVAD-fmk effec-
tively inhibited the cysteine cathepsin activity, Hsp70 at
concentrations up to 5  M was without an effect (Fig. 1
C). Moreover, Hsp70 did not directly bind the most abun-
dant cysteine cathepsins (B or L) as judged by the inability
of Hsp70 to coimmunoprecipitate cysteine cathepsins or
vice versa (unpublished data). To investigate the second
possibility, we analyzed the subcellular distribution of ca-
thepsins B and L using specific antibodies and confocal mi-
croscopy. In contrast with untreated and  -Gal–infected
cells that displayed mainly perinuclear punctuate distribu-
tion of cathepsins consistent with their lysosomal localiza-
tion, cathepsins B and L translocated from cytosolic gran-
ules to the cytosol and nucleus in Ad.asHsp70-treated
cancer cells (Fig. 1, D–F). To evaluate the kinetics and the
extent of the lysosomal permeabilization, we also measured
the activities of lysosomal enzymes in cytosolic fractions
obtained by digitonin-based plasma membrane permeabili-
zation (6). Although the total cellular cysteine cathepsin ac-
tivity remained essentially unchanged, the cytosolic frac-
tions of Ad.asHsp70-infected cells contained  8, 20, and
25% of the total cellular cysteine cathepsin activity 24, 48,
and 60 h after the Ad.asHsp70 infection, respectively (Fig.
1 G). The cytosolic enzyme activity in vehicle-treated and
Ad. -Gal–infected cells remained  2% of the total activity
throughout the experiment (Fig. 1 G). Notably, the gross
morphological changes indicative of PCD (detachment,
shrinkage, and chromatin condensation) and the decrease
in cell survival as measured by MTT reduction or LDH re-
lease assays were first detectable several hours after the ap-
pearance of cathepsin activity in the cytosol,  60 h after
the Ad.asHsp70 infection (Fig. 1 A and reference 29).
NAG, a 250-kD enzyme present in the lysosomes of un-
treated cells, was also released into the cytosol of MCF-7
cells upon Ad.asHsp70 infection (Fig. 1 H). However, the
kinetics of the NAG release were clearly slower than that of
cysteine cathepsins. Nontumorigenic immortalized breast
epithelial cells (HBL-100) that are resistant to the Hsp70
depletion (29) showed no increase in the cytosolic cysteine
cathepsin (Fig. 1 I) or NAG (not depicted) activities 24–96
h after the Ad.asHsp70 infection.
Hsp70 Inhibits TNF- and Etoposide-induced LMP. Hsp70
confers effective protection against TNF-induced cell death
in ME-180 cervix carcinoma and WEHI-S fibrosarcoma
cells without inhibiting the activation of caspases (28). Al-
though TNF-induced death of ME-180 cervix carcinoma
cells is strictly caspase dependent, that of WEHI-S fibrosar-
coma cells is completely independent of caspase activity
and can even be enhanced by pan-caspase and caspase-8 in-
hibitors (6). However, both death pathways depend on the
activity of cathepsin B, which is released from the lysoso-
mal compartment into the cytosol upon TNF treatment ei-
ther in a caspase-dependent (ME-180 cells) or caspase-
inhibited (WEHI-S) manner (6). Next, we studied whether
Figure 2. Hsp70 inhibits TNF-induced lysosomal release of cysteine ca-
thepsins in tumor cells. Vector and Hsp70-transfected WEHI-S clones (A–D)
or vector- and asHsp70-transfected ME-180 cells (E and F) were treated as
indicated and analyzed for the cytosolic cysteine cathepsin activity (arbitrary
units) as a measure of LMP (B, D, and F) and for the released LDH activity
(percentage of total activity) as a measure of cytotoxicity (A, C, and E). The
values represent means of a triplicate determination   SD. The experi-
ments were repeated twice with essentially similar results.Hsp70 Inhibits Lysosomal Permeabilization 430
Hsp70 interfered with LMP and cathepsin release in TNF-
induced WEHI-S and ME-180 cells. WEHI-S cells ex-
pressing Hsp70 resisted not only the death induced by
TNF (Fig. 2 A) but also the enhanced cytotoxicity induced
by the combination of TNF plus 1  M zVAD-fmk (Fig. 2
C). The Hsp70-mediated protection was associated with a
complete inhibition of the appearance of the cysteine ca-
thepsin activity in the cytosol (Fig. 2, B and D). Also, in
ME-180v cells expressing high levels of endogenous
Hsp70, TNF failed to induce the translocation of cathep-
sins and death, whereas ME-180as cells that express low
levels of Hsp70 due to the transfection of an as Hsp70
cDNA that responded to TNF by releasing cysteine ca-
thepsins into the cytosol before the lysis of the plasma
membrane (Fig. 2, E and F).
To extend the analysis to other cell types and death stim-
uli, we established iMEFs originating from wild-type (iMEF
wt-1 and -5) and Hsp70 transgenic mice (iMEF hsp-3 and
-4). The iMEFs from the transgenic animals expressed con-
siderably higher levels of Hsp70 than the cells from the
wild-type animals (Fig. 3 A). However, the expression
level was below that observed in most human cancer cell
lines. The moderate expression level of Hsp70 was suffi-
cient to confer significant protection against cell death in-
duced by TNF plus cycloheximide (CHX) or etoposide (a
topoisomerase inhibitor), but not against that induced by
Fas ligand plus CHX (Fig. 3 B). Next, we studied the in-
volvement of LMP, mitochondria, cysteine cathepsins, and
caspases in the death programs inhibited by Hsp70. Inhibi-
tion of cysteine cathepsin activity in iMEFs by 50  M
zFA-fmk conferred significant protection against death in-
duced by TNF plus CHX or etoposide, whereas inhibition
of caspases by 10  M zVAD-fmk protected iMEFs only
against TNF plus CHX (Fig. 3 C). Both stimuli induced an
early LMP in wild-type iMEFs as demonstrated by the re-
lease of cysteine cathepsin activity into the cytosol (Fig. 3,
D and E). In both cases, the LMP was almost completely
attenuated in iMEFs originating from Hsp70 transgenic an-
imals. Both stimuli also induced mitochondrial outer mem-
brane permeabilization as demonstrated by the release of
cytochrome c from the mitochondrial intermembrane space
into the cytosol (Fig. 3 F) and effector caspase activation
(not depicted) in wild-type iMEFs. Both cytochrome c
release and effector caspase activation were significantly at-
tenuated in Hsp70-expressing iMEFs. Furthermore, zFA-
fmk, a pharmacological cysteine cathepsin inhibitor, effec-
tively inhibited TNF- and etoposide-induced cytochrome
c release in iMEFs, indicating that cytochrome c release re-
quires cathepsin activity (Fig. 3 F). This is consistent with
our earlier data showing that TNF plus CHX fails to in-
duce cytochrome c release and effector caspase activation in
cathepsin B–deficient iMEFs (34). Thus, Hsp70 interfered
Figure 3. Hsp70 inhibits TNF- and eto-
poside-induced death upstream of LMP and
mitochondrial outer membrane permeabili-
zation in iMEFs. (A) An immunoblot dem-
onstrating the moderate expression level of
the Hsp70 transgene in iMEFs originating
from Hsp70 transgenic animals (hsp-3 and -4).
iMEFs from wild-type animals (wt-1 and -5)
express barely detectable levels of Hsp70
(visible in longer exposure). Proteins from
MCF-7 cells serve as a positive control, and
immunoblot for GAPDH demonstrates the
fairly equal loading of the protein. (B and
C) The sensitivity of the iMEFs to TNF
(1 ng/ml murine TNF plus 4  M CHX for
18 h), etoposide (Eto; 50  M for 48 h), and
Fas ligand (2.5% Fas ligand–containing su-
pernatant plus 4  M CHX for 18 h) in the
absence or presence of 10  M zVAD-fmk
(zVAD) or 50  M zFA-fmk (zFA) was
evaluated by MTT reduction assay, and the
survival is expressed as the percentage of
untreated cells. (D and E) iMEFs were
treated with 1 ng/ml TNF plus 4  M CHX
(D) or 50  M etoposide (E) for indicated
times and analyzed for the cytosolic cysteine
cathepsin activity as a measure of LMP. The
values represent percentages of total activity.
(F) iMEFs were grown on coverslips,
treated with 1 ng/ml TNF plus 4  M CHX
for 8 h or 50  M etoposide for 48 h, fixed,
and analyzed for cytochrome c release by
immunostaining. When indicated cells were
pretreated for 1 h with 50  M zFA-fmk
(zFA). A minimum of 500 cells were counted, and the values represent the percentages of cells with diffuse (extra-mitochondrial) cytochrome c staining.
(B–E) The values represent the means of a triplicate determination   SD. All assays were repeated at least once with essentially similar results, and addi-
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with these cell death programs by inhibiting LMP, which
occurred upstream of mitochondrial outer membrane per-
meabilization and effector caspase activation.
The aforementioned data showing that Ad.asHsp70 trig-
gers LMP and that Hsp70 inhibits LMP and cathepsin re-
lease in TNF-treated WEHI-S and ME-180 cells as well as
in TNF- or etoposide-treated iMEFs support the previously
published data showing that Hsp70 prevents PCD either
upstream of mitochondrial outer membrane permeabiliza-
tion (iMEFs), downstream of effector caspase activation
(ME-180), or independent of both (WEHI-S and Ad.asHsp70-
treated cancer cells). Accordingly, recombinant Hsp70 had
no effect on the activation of apoptosome as demonstrated
by its inability to inhibit cytochrome c plus dATP-induced
effector caspase activation as well as processing of caspases or
their substrates in an in vitro assay system optimized and
successfully used to screen small molecule libraries for apop-
tosome inhibitors (Fig. 4 and reference 33). Furthermore,
cytochrome c plus dATP induced similar caspase activation
in cytosols with high versus low Hsp70 content (i.e., cyto-
sols from WEHI-hsp-2 vs. WEHI-v2 and iMEF-wt-5 vs.
iMEF-hsp-4; unpublished data).
Hsp70 Localizes to the Lysosomal Membranes. In addition
to its localization in the cytosol of unstressed normal cells,
most cultured tumor cells as well as freshly isolated tumors
present Hsp70 on the cell surface (16, 17). Using an Hsp70-
specific antibody that recognizes the extracellular epitope of
the membrane-associated Hsp70, we studied whether cells
expressing Hsp70 on the plasma membrane also have it lo-
calized in intracellular membranes. For this purpose, we
used the CX2 colon carcinoma cells separated by fluores-
cence-associated cell sorter into stable CX  and CX  sub-
clones with  80% and  20% of cells positive for surface
Hsp70, respectively (17). Notably, the total level of Hsp70
in CX  and CX  cells was indistinguishable (17). Immuno-
electron microscopy revealed high levels of Hsp70 on the
plasma membrane and in the membranes of the intracellular
vacuolar structures of CX  cells (Fig. 5 A). Costaining with
cathepsin D showed a colocalization of cathepsin D and
Hsp70 in the intracellular vesicles as well as on the cell sur-
face in CX  (Fig. 5, B and C), but not in CX  cells (Fig. 5
D). Quantification of the costaining in three CX  and four
CX  cells revealed that, on average, 10%   1% and 62%  
25% of cathepsin D positive vesicles contained Hsp70, re-
spectively (Fig. 5 E). Thus, tumor-associated surface expres-
sion of Hsp70 was associated with the localization of Hsp70
to the endosomal/lysosomal compartment.
To address more directly whether Hsp70 is attached to
the membranes of the endosomal/lysosomal compartment,
next we fractionated the iMEFs originating from the
Hsp70 transgenic animals and performed immunoblot anal-
ysis of proteins from various cellular fractions. As expected,
most of the Hsp70 was found in the cytosolic and heavy
membrane fractions (Fig. 5 F). However, considerable
amount of Hsp70 was detected in the light membrane frac-
tion (cellular organelles including endosomes and lyso-
somes) together with most of the cellular cathepsin B. Per-
meabilization of the organelles in the light membrane
fraction with digitonin resulted in the total release of ca-
thepsin B into the supernatant, whereas a large part of
Hsp70 remained in the pellet, suggesting that it was bound
to the membranes of the intracellular organelles.
To examine whether the lysosomal localization of Hsp70
had any effect on the lysosomal stability permeability and
size, we first measured the longest diameters of 19 and 13
cathepsin D positive vesicles in CX  and CX  cells, respec-
tively, and calculated the theoretical volumes of the vesicles.
As demonstrated in the Fig. 6 A, the average volume of ca-
thepsin D positive vesicles was almost four times larger in
CX  than in CX  cells. Immunoelectron microscopy does
not allow the estimation of the number of the vesicles/cell
and, therefore, next we measured the total volume of the
acidic compartment in CX  and CX  cells by flow cytom-
etry after staining with acridine orange, a lysosomotrophic
base that accumulates in the acidic lysosomal compartment
and emits red fluorescence when in high concentration.
Based on three independent measurements, the mean inten-
sity of the red fluorescence was 2.13   0.47 times higher
(P   0.003) in CX  cells than in CX  cells (Fig. 6 B). Sim-
ilar results were obtained when comparing Hsp70-trans-
Figure 4. Hsp70 does not inhibit the apoptosome-
mediated activation of caspases. Cytosolic extracts pre-
pared from HeLa cells were incubated for 90 min with 1
 M cytochrome c and 1 mM dATP (Cc/dATP) in the
presence or absence of 2  M of recombinant human
Hsp70, 1  M zVAD-fmk, or 0.1  M DEVD-fmk.
(A) Caspase-3–like activity was assessed by spectrofluo-
rometric quantification of DEVD-AFC cleavage and
presented as pmol per min. (B) Thereafter, samples
were analyzed by immunoblotting using antibodies spe-
cific against the indicated proteins. *, a background band.
Vertical lines indicate that intervening lanes have been
spliced out. The experiment was repeated twice with
similar results.Hsp70 Inhibits Lysosomal Permeabilization 432
fected and vector-transfected WEHI-S cells (1.89   0.20
times higher; P   0.016; Fig. 6 C) as well as Hsp70-trans-
genic and wild-type iMEFs (1.77   0.29 times higher; P  
0.01; Fig. 6 D). The increased volume of the acidic com-
partment as well as the larger size of individual lysosomes in
Hsp70-expressing cells was also evident when cells stained
with acridine orange were visualized by confocal micros-
copy (Fig. 6 E). Furthermore, the increase in the volume of
the acidic compartment correlated with the increased total
cysteine cathepsin activity (Fig. 6, F and G) and protein
level as analyzed by immunoblotting (not depicted), sug-
gesting that, indeed, Hsp70 stabilized lysosomal membranes.
Next, we compared the stability of CX  and CX  lyso-
somes by analyzing the LMP after exposure to oxidative
stress (H2O2) or photolysis (blue light, 450–500 nm). For
this purpose, lysosomes were stained and activated with
Figure 5. Hsp70 is localized on lysosomal membranes. Representative cryo-ultramicrotomy images of Hsp70 membrane positive CX  (A–C) and
membrane negative CX  (D) tumor cells labeled either with a murine anti-Hsp70 antibody alone (A) or together with rabbit anti-cathepsin D antibodies
(B–D) are shown. (A) Localization of Hsp70 (10 nm gold particles) can be detected in the cytosol, plasma membrane and intracellular vesicles of CX 
tumor cells. (B and C) Colocalization of Hsp70 (visualized by 10-nm gold particles) and cathepsin D (visualized by 5-nm gold particles) in intracellular
vesicles and on the plasma membrane can be detected in CX  cells. (D) In CX  tumor cells, only minimal amounts of Hsp70 were detectable in cathepsin D
positive vesicles. (E) The percentage of Hsp70 positive vesicles of all cathepsin D positive vesicles was calculated in pictures of 3 CX  and 4 CX  cells.
The number of cathepsin D positive vesicles/picture is indicated (top of bars). (F) iMEF-hsp-4 cells were fractionated as described in Materials and Methods,
and the proteins from the indicated fractions originating from the indicated amount of cells were analyzed by immunoblotting with rabbit and goat anti-
bodies against Hsp70 and cathepsin B, respectively. Where indicated, the samples were incubated with a buffer containing 800  g/ml digitonin to per-
meabilize the membranes. Cyt, cytoplasm; HM, heavy membrane; LM, light membrane; S-LM, supernatant of the LM.
Figure 6. Hsp70 increases the volume of the
acidic compartment and total cellular cysteine ca-
thepsin activity. (A) The diameters of cathepsin D
positive vesicles in representative cryo-ultramicrot-
omy images (magnification, 23,000) of CX  (n  
19) and CX  (n   13) tumor cells labeled with ca-
thepsin D antibody were measured. The values
present theoretical volumes of the vesicles calcu-
lated with the formula 4/3    r3   SD. P   0.05.
(B–E) CX  and CX  (B), WEHI-hsp-2 and
WEHI-V-2 (C), and iMEF-hsp-4 and iMEF-wt-5
(D and E) cells were labeled with acridine orange,
and the total volume of the acidic compartment
(VAC) was measured by flow cytometry (B–D) or
visualized by confocal microscopy (E). (F and G)
The total cysteine cathepsin activities in cell lysates
of CX  and CX  cells (F) and vector-transfected
(V-2 and V-3) and Hsp70-transfected (Hsp-2 and
Hsp-18) WEHI-S clones (G) were measured as de-
scribed in Materials and Methods. The values rep-
resent means of triplicate determinations. All exper-
iments were repeated two to four times with
essentially similar results.Nylandsted et al. 433
acridine orange before the challenge, and the permeabiliza-
tion of lysosomes was analyzed by measuring the emission
of green fluorescence indicative of the leakage of acridine
orange from the acidic compartment to the cytosol (10).
The Hsp70 positive lysosomes of CX  cells were signifi-
cantly more resistant to H2O2 than Hsp70 negative lyso-
somes of CX  cells (Fig. 7 A). Although 30-min treatment
with 5  M H2O2 triggered a 1.9-fold increase in the green
fluorescence in CX  cells,  10 times higher concentra-
tions were required for a similar effect in CX  cells. The
decreased permeability of the lysosomes correlated with the
increased survival of the CX  cells as analyzed by the MTT
reduction assay 24 h after the H2O2 treatment (Fig. 7 B).
Furthermore, CX  cells were clearly more resistant to
 -irradiation–induced apoptosis than CX  cells (Fig. 7 C).
Furthermore, lysosomes of CX  cells tolerated longer ex-
posures to blue light than those of CX  cells (Fig. 7 D).
Also, the lysosomes of Hsp70-transgenic iMEFs tolerated
blue light better than those of wild-type iMEFs (Fig. 7 E).
Counting of acridine orange positive (red) lysosomes be-
fore and immediately after 25-s exposure to blue light
showed that, whereas 36.7   7.5% of lysosomes in wild-
type cells (nine cells) had permeabilized, only 16.2  
10.4% of lysosomes in Hsp70-transgenic iMEFs had lost
the red staining (P   0.001).
Discussion
The data presented here demonstrate that Hsp70 is local-
ized to the membranes of the endosomal/lysosomal com-
partment of tumor cells and that it inhibits lysosomal per-
meabilization induced by such diverse stimuli as cytokines,
anticancer drugs,  -irradiation, oxidative stress, and photol-
ysis. Furthermore, the mere depletion of Hsp70 from tu-
mor cells triggered LMP and cathepsin-mediated PCD.
Thus, the main mechanism by which Hsp70 confers a sur-
vival advantage to tumor cells appears to be the inhibition
of the permeabilization of lysosomal membranes and/or
membranes of other vesicles containing cathepsins. This
may explain the widely demonstrated ability of Hsp70 to
protect tumor cells against the diverse death stimuli that all
trigger LMP, but may kill cells in a caspase-dependent or
-independent manner (15, 35, 36). Solid tumors com-
monly show increased expression levels, plasma membrane
association, and secretion of cathepsins (37). Such changes
have been considered tumor promoting because they often
correlate positively with invasive and metastatic capacity of
tumors. However, accumulating data suggest that the in-
creased expression and altered trafficking of lysosomal
proteases may also form an “Achilles heel” for the tumor
because stress-induced leakage of cathepsins from the lyso-
somal compartment to the cytosol can trigger PCD (35, 36,
38). Data presented here clearly demonstrate that tumor
cells can escape the death induced by lysosomal proteases
by increasing the expression of Hsp70, which effectively
inhibits the release of lysosomal proteases into the cytosol.
The membrane localization of Hsp70 appears to be crucial
for its ability to inhibit LMP. This is demonstrated here us-
ing CX  and CX  sublines of CX2 colon cancer cells that
differ from each other only in their membrane expression,
but not in the total level, of Hsp70 (17). Hsp70 plasma
membrane expression has been found in  80% of freshly
isolated human biopsy samples from solid tumors of various
origins and leukemic blasts from patients with acute mye-
logenous leukemia (16, 39). Because normal tissues and
bone marrows of healthy human individuals do not express
Hsp70 on the cell surface, Hsp70 can be considered a tu-
mor-selective membrane structure. Supporting our data,
showing that Hsp70 is directly associated with the mem-
branes, it has been shown previously that it binds lipids in
Figure 7. Hsp70 protects lysosomal membranes against permeabiliza-
tion induced by oxidative stress or photolysis. (A–D) CX  (black bars)
and CX  (white bars) cells were treated for 30 min (A) or 24 h (B) with
indicated concentrations of H2O2, exposed to 2   10 Gy  -irradiation
(C) or indicated times of blue light (D). Cells prestained with acridine
orange were analyzed immediately afterwards (A) or 45 min after the
treatment (D) for lysosomal leakage by flow cytometry (green fluores-
cence). The values represent the fold increases in the mean intensity of
the green fluorescence. (B) The viability of the cells was analyzed 24 h
after the treatment by the MTT reduction assay and is expressed as the
percentage of untreated cells. (C) The number of apoptotic cells was ana-
lyzed by annexin V staining and is expressed as fold increase as compared
with the untreated cells. (E) Wild-type and Hsp70-expressing iMEFs
prestained with acridine orange were exposed to the 488-nm laser of the
confocal microscope (10-s preexposure and 15-s imaging). Representa-
tive cells are shown. Notice the better preservation of the lysosomes in
Hsp70-expressing cells. The experiments were repeated twice with sim-
ilar results. The values represent averages   SD of three independent
experiments (A–D) or averages of 12 measurements.Hsp70 Inhibits Lysosomal Permeabilization 434
vitro (40). How Hsp70 localizes to the lysosomes and
plasma membrane of tumor cells is still an open question.
The inability of inhibitors of endoplasmic reticulum (Golgi
route; i.e., brefeldin A and colchicine) to inhibit the plasma
membrane localization of Hsp70 suggests that the transport
occurs via an alternative cytoplasmic protein export route
(41). Interestingly, only the cells with surface expression of
Hsp70 had Hsp70 also in the membranes of endosomal/
lysosomal compartment and showed plasma membrane ex-
pression of cathepsin D. Thus, Hsp70 may be transported
to the plasma membrane together with cathepsins via the
lysosomal exocytosis and back to the cells via endocytosis.
It should be noted here that Hsc70, the cognate member of
the Hsp70 family, also associates with lysosomes (42). To-
gether with numerous cochaperones, it assists the delivery
of proteins to be degraded in the lysosomal compartment.
Thus, Hsp70 may also be involved in the delivery of pro-
teins to the lysosomes and the protective effect could be
due to the removal of toxic proteins or protein aggregates.
Interestingly, both increased expression and secretion of
cathepsins as well as sensitivity to the lysosomal death path-
way are associated with an aggressive tumor phenotype (34,
37). We are presently studying whether the lysosomal lo-
calization of Hsp70 and cathepsin secretion are coregulated
during tumorigenesis. Because the mere depletion of Hsp70
from tumor cells, but not from normal cells, triggered
LMP, one might speculate that Hsp70 is required for the
stability of the tumor-specific subpopulation of lysosomes,
possibly the same subpopulation that is responsible for the
transport of cathepsins to the plasma membrane and extra-
cellular space where they contribute to the invasiveness of
the tumor. Thus, the better understanding of the mecha-
nisms underlying the lysosomal localization and function of
Hsp70 may provide promising targets for the future cancer
therapy.
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